Literature DB >> 2646026

Macrophage colony-stimulating factor enhances monocyte and macrophage antibody-dependent cell-mediated cytotoxicity.

R A Mufson1, J Aghajanian, G Wong, C Woodhouse, A C Morgan.   

Abstract

In vitro culture of either human peripheral blood monocytes or murine peritoneal macrophages for 72 hr in the presence of macrophage colony-stimulating factor (M-CSF) dramatically increased their subsequent ability to mediate antibody-dependent cellular cytotoxicity (ADCC). The M-CSF-treated cells were more effective in ADCC at lower effector to target cell ratios and in the presence of lower concentrations of tumor-specific monoclonal antibody than the untreated control cells. Two other hematopoietic cytokines, granulocyte-macrophage colony-stimulating factor and interleukin-3, reported to enhance other macrophage effector functions were ineffective in promoting the development of ADCC by cultured human monocytes. All three hematopoietic growth factors were capable of enhancing the ability of the cultured monocytes to secrete TNF alpha; however, TNF alpha is unlikely to be an important cytotoxic factor in ADCC because neutralizing antibodies against TNF alpha had no affect on ADCC in vitro. Further, much higher concentrations of M-CSF were required to augment monocyte TNF alpha release (20-100 ng/ml) than ADCC capacity (1-10 ng/ml). These results suggest that M-CSF administration might prove effective in increasing the tumoricidal activities of tumor-specific monoclonal antibodies by enhancing the capacity of monocytes and macrophages to mediate ADCC.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2646026     DOI: 10.1016/0008-8749(89)90234-7

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  13 in total

1.  Role of macrophage colony-stimulating factor in the differentiation and expansion of monocytes and dendritic cells from CD34+ progenitor cells.

Authors:  A W Kamps; D Hendriks; J W Smit; E Vellenga
Journal:  Med Oncol       Date:  1999-04       Impact factor: 3.064

2.  Thromboxane receptor signaling is required for fibronectin-induced matrix metalloproteinase 9 production by human and murine macrophages and is attenuated by the Arhgef1 molecule.

Authors:  John M Hartney; Claire E Gustafson; Russell P Bowler; Roberta Pelanda; Raul M Torres
Journal:  J Biol Chem       Date:  2011-11-15       Impact factor: 5.157

3.  Antitumor immunity induced by irradiated tumor cells producing macrophage colony-stimulating factor.

Authors:  S Suzu; F Kimura; M Tanaka-Douzono; M Yamada; Y Nakamura; N Wakimoto; K Sato; T Morita; K Ikeda; K Motoyoshi
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

4.  Transformation of rat glioma cells with the M-CSF gene inhibits tumorigenesis in vivo.

Authors:  H Yoshioka; S Hama; T Sadatomo; E Taniguchi; K Harada; K Sugiyama; F Kimura; K Motoyoshi; K Kurisu
Journal:  J Neurooncol       Date:  1998-12       Impact factor: 4.130

5.  Antibody-independent phagocytosis of tumor cells by human monocyte-derived macrophages cultured in recombinant macrophage colony-stimulating factor.

Authors:  D H Munn; N K Cheung
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

6.  Macrophage colony-stimulating factor mRNA and protein in atherosclerotic lesions of rabbits and humans.

Authors:  M E Rosenfeld; S Ylä-Herttuala; B A Lipton; V A Ord; J L Witztum; D Steinberg
Journal:  Am J Pathol       Date:  1992-02       Impact factor: 4.307

7.  Effect of macrophage colony-stimulating factor on anticryptococcal activity of bronchoalveolar macrophages: synergy with fluconazole for killing.

Authors:  E Brummer; F Nassar; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

8.  Tumoricidal effect of human macrophage-colony-stimulating factor against human-ovarian-carcinoma-bearing athymic mice and its therapeutic effect when combined with cisplatin.

Authors:  T Adachi; H Mano; Y Shinohara; T Nakanishi; T Suzuki; K Ino; N Kato; T Okamoto; A Nawa; S Goto
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

9.  Systemic T cell-independent tumor immunity after transplantation of universal receptor-modified bone marrow into SCID mice.

Authors:  K M Hege; K S Cooke; M H Finer; K M Zsebo; M R Roberts
Journal:  J Exp Med       Date:  1996-12-01       Impact factor: 14.307

10.  Activity of 8F4, a T-cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo.

Authors:  A Sergeeva; H He; K Ruisaard; L St John; G Alatrash; K Clise-Dwyer; D Li; R Patenia; R Hong; P Sukhumalchandra; M J You; M Gagea; Q Ma; J J Molldrem
Journal:  Leukemia       Date:  2016-03-08       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.